Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,569 | 117 | 95.1% |
| Education | $184.94 | 3 | 4.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $523.68 | 14 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $371.07 | 9 | $0 (2022) |
| Daiichi Sankyo Inc. | $285.37 | 4 | $0 (2022) |
| Amgen Inc. | $233.03 | 12 | $0 (2022) |
| Celgene Corporation | $205.89 | 10 | $0 (2023) |
| Millennium Pharmaceuticals, Inc. | $198.60 | 2 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $146.20 | 8 | $0 (2022) |
| Adaptive Biotechnologies Corporation | $144.72 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $142.88 | 9 | $0 (2020) |
| SERVIER PHARMACEUTICALS LLC | $138.48 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $373.93 | 4 | Genentech USA, Inc. ($148.75) |
| 2023 | $366.46 | 8 | Genentech USA, Inc. ($149.60) |
| 2022 | $290.32 | 14 | Celgene Corporation ($79.99) |
| 2021 | $318.68 | 7 | Servier Pharmaceuticals LLC ($125.85) |
| 2020 | $193.44 | 5 | Daiichi Sankyo Inc. ($125.00) |
| 2019 | $907.49 | 35 | AstraZeneca Pharmaceuticals LP ($156.07) |
| 2018 | $167.75 | 12 | Amgen Inc. ($53.63) |
| 2017 | $1,136 | 35 | Millennium Pharmaceuticals, Inc. ($198.60) |
All Payment Transactions
120 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $144.72 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $65.79 | General |
| Category: Oncology | ||||||
| 05/10/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: NONE | ||||||
| 05/01/2024 | Genentech USA, Inc. | Lunsumio (Biological), Columvi | Food and Beverage | In-kind items and services | $148.75 | General |
| Category: BioOncology | ||||||
| 11/30/2023 | Genentech USA, Inc. | Polivy (Biological), Columvi | Food and Beverage | In-kind items and services | $129.76 | General |
| Category: BioOncology | ||||||
| 08/21/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.54 | General |
| Category: Hematology | ||||||
| 06/19/2023 | AVEO Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: Oncology | ||||||
| 06/08/2023 | SOBI, INC | Doptelet (Drug) | Food and Beverage | In-kind items and services | $113.87 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/17/2023 | Genentech USA, Inc. | Gazyva (Biological), Venclexta | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: BioOncology | ||||||
| 05/10/2023 | Puma Biotechnology, Inc. | — | Food and Beverage | In-kind items and services | $18.79 | General |
| 04/11/2023 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $17.40 | General |
| Category: Oncology | ||||||
| 04/10/2023 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $30.62 | General |
| Category: Oncology | ||||||
| 09/20/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $23.74 | General |
| Category: Hematology | ||||||
| 09/07/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: ONC | ||||||
| 08/25/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: ONCOLOGY | ||||||
| 08/16/2022 | Astellas Pharma US Inc | PADCEV (Drug) | Food and Beverage | In-kind items and services | $21.75 | General |
| Category: Oncology | ||||||
| 08/10/2022 | Foundation Medicine, Inc. | FOUNDATIONONE (Device), FOUNDATIONONE HEME, FOUNDATIONONE CDX | Food and Beverage | In-kind items and services | $18.33 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2022 | Cepheid | — | Food and Beverage | In-kind items and services | $18.42 | General |
| 06/06/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: Oncology | ||||||
| 05/31/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Oncology | ||||||
| 05/17/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $30.61 | General |
| Category: Hematology | ||||||
| 05/10/2022 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: ONCOLOGY | ||||||
| 03/29/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $17.04 | General |
| Category: ONCOLOGY | ||||||
| 03/22/2022 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $25.64 | General |
| Category: Hematology | ||||||
| 03/15/2022 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 330 | 379 | $82,647 | $33,106 |
| 2022 | 5 | 320 | 579 | $226,736 | $56,252 |
| 2021 | 5 | 271 | 464 | $141,106 | $45,100 |
| 2020 | 47 | 4,514 | 48,001 | $1.4M | $214,065 |
All Medicare Procedures & Services
66 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 82 | 109 | $23,342 | $11,167 | 47.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 100 | 112 | $16,912 | $7,873 | 46.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $19,805 | $7,399 | 37.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 20 | 29 | $13,862 | $3,262 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $4,619 | $1,560 | 33.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 23 | $2,254 | $1,180 | 52.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 12 | 12 | $1,853 | $664.76 | 35.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 127 | 296 | $131,720 | $32,424 | 24.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 105 | 191 | $60,165 | $14,207 | 23.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 43 | 43 | $23,435 | $5,884 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 20 | 20 | $4,920 | $2,330 | 47.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 25 | 29 | $6,496 | $1,408 | 21.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 107 | 240 | $89,629 | $27,206 | 30.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 107 | 167 | $36,973 | $12,419 | 33.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 26 | 26 | $6,706 | $2,496 | 37.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $5,962 | $2,167 | 36.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 15 | 15 | $1,836 | $811.68 | 44.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 33 | 3,060 | $159,120 | $45,654 | 28.7% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2020 | 36 | 29,580 | $147,900 | $24,323 | 16.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2020 | 37 | 3,050 | $122,000 | $23,964 | 19.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 147 | 317 | $70,374 | $23,568 | 33.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 232 | 375 | $65,625 | $18,001 | 27.4% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 32 | 123 | $55,596 | $12,301 | 22.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 326 | 716 | $65,156 | $5,442 | 8.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 36 | 73 | $11,242 | $4,634 | 41.2% |
About Dr. Katerina Erokhina, D.O
Dr. Katerina Erokhina, D.O is a Internal Medicine healthcare provider based in Vancouver, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/16/2012. The National Provider Identifier (NPI) number assigned to this provider is 1437404571.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Katerina Erokhina, D.O has received a total of $3,754 in payments from pharmaceutical and medical device companies, with $373.93 received in 2024. These payments were reported across 120 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($3,569).
As a Medicare-enrolled provider, Erokhina has provided services to 5,435 Medicare beneficiaries, totaling 49,423 services with total Medicare billing of $348,523. Data is available for 4 years (2020–2023), covering 66 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology, Hematology & Oncology
- Location Vancouver, WA
- Active Since 07/16/2012
- Last Updated 07/16/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1437404571
Products in Payments
- NINLARO (Drug) $211.18
- TAGRISSO (Drug) $206.59
- Lunsumio (Biological) $148.75
- clonoSEQ (Device) $144.72
- TIBSOVO (Drug) $138.48
- Avastin (Biological) $135.42
- Imbruvica (Drug) $130.37
- Polivy (Biological) $129.76
- KEYTRUDA (Biological) $127.75
- Doptelet (Drug) $125.18
- Enhertu (Drug) $125.00
- INJECTAFER (Drug) $117.95
- THERASPHERE-BIO (Device) $114.24
- FARYDAK (Drug) $106.54
- CYRAMZA (Drug) $97.33
- LYNPARZA (Drug) $88.19
- VELCADE (Drug) $85.20
- REBLOZYL (Biological) $71.89
- Neulasta (Biological) $70.89
- Epkinly (Drug) $65.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Vancouver
Dr. Jaime Aranda-Michel, Md, MD
Internal Medicine — Payments: $190,413
Dr. Nicholas Wysham, M.d, M.D
Internal Medicine — Payments: $115,959
Dr. Nora Bucher, Md, MD
Internal Medicine — Payments: $92,601
Dr. Troy Dillard, Md, MD
Internal Medicine — Payments: $25,011
Dr. Kameron Ferdowsali, M.d, M.D
Internal Medicine — Payments: $23,197
Mahesh Dangal, M.d, M.D
Internal Medicine — Payments: $19,705